Establishment Labs Holdings Inc. key statistics and ratios
In fiscal 2025, Establishment Labs Holdings Inc. had return on equity of -133.3%, an operating margin of -18.5%, debt equal to 1051.2% of equity and a current ratio of 3.04. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 51.0% | 59.0% | 61.3% | 62.0% | 67.4% | 65.9% | 64.8% | 66.0% | 69.3% | 70.5% |
| Operating margin | −57.6% | −39.0% | −34.5% | −33.0% | −19.8% | −24.5% | −39.4% | −30.1% | −18.5% | −7.6% |
| Net margin | −100.6% | −34.5% | −42.6% | −45.0% | −32.5% | −46.5% | −47.5% | −51.0% | −24.2% | −15.8% |
| Free-cash-flow margin | −94.8% | −58.2% | −40.5% | −17.3% | −23.6% | −34.0% | −58.4% | −38.9% | −27.0% | −16.9% |
| Return on equity | — | −65.4% | −69.9% | −66.5% | −65.5% | — | — | — | −133.3% | −172.3% |
| Return on assets | −61.1% | −24.3% | −32.7% | −27.9% | −27.8% | −42.9% | −32.7% | −27.5% | −14.5% | −11.0% |
| Asset turnover | 0.61 | 0.70 | 0.77 | 0.62 | 0.86 | 0.92 | 0.69 | 0.54 | 0.60 | 0.69 |
| Current ratio | 0.69 | 6.05 | 4.12 | 5.11 | 3.55 | 3.85 | 3.06 | 3.56 | 3.04 | 3.84 |
| Debt to equity | — | 32.1% | 121.5% | 66.5% | 102.3% | — | >999% | 413.6% | >999% | >999% |
| Interest cover (operating income ÷ interest) | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m |
| R&D as % of revenue | 19.8% | 20.7% | 16.7% | 16.3% | 14.5% | 12.5% | 16.0% | 11.9% | 9.6% | 8.3% |
| SG&A as % of revenue | 88.9% | 77.3% | 79.1% | 78.7% | 72.8% | 77.9% | 88.1% | 84.2% | 78.2% | 69.9% |
| Capital spending as % of revenue | 2.6% | 2.8% | 7.0% | 2.5% | 1.9% | 1.8% | 4.8% | 3.7% | 2.9% | 3.7% |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 63.9% | 68.5% | 67.2% | 68.8% | 70.1% | 70.5% | 70.7% | 70.6% |
| Operating margin | −32.7% | −41.9% | −41.0% | −27.5% | −7.5% | −6.1% | −10.9% | −6.4% |
| Net margin | −41.5% | −77.6% | −50.1% | −32.3% | −20.7% | −4.0% | −22.3% | −17.4% |
| Free-cash-flow margin | −34.6% | −47.8% | −51.9% | −39.7% | −24.4% | −3.1% | −10.3% | −30.0% |
| Current ratio | 3.62 | 3.56 | 3.36 | 2.84 | 3.33 | 3.04 | 2.96 | 3.84 |
| Debt to equity | 594.2% | 413.6% | 571.6% | 993.4% | >999% | >999% | >999% | >999% |
| R&D as % of revenue | 11.9% | 11.6% | 12.2% | 10.1% | 8.5% | 8.4% | 8.8% | 7.5% |
| SG&A as % of revenue | 84.7% | 98.9% | 95.9% | 86.1% | 69.1% | 68.1% | 72.8% | 69.4% |
Financial health
- Short-term assets cover short-term liabilities $248m of assets due within a year against $65m of liabilities due within a year.
- Short-term assets cover long-term liabilities $248m short-term assets against $266m of longer-dated liabilities.
- More cash than debt $71m of cash against $262m of debt.
- Debt below 40% of shareholders' equity Debt is 1211% of equity.
- Debt burden no higher than five years ago Debt to equity moved from 102% to 1211% over five years.
- A year's operating cash flow covers at least 20% of debt −$32m of operating cash flow against $262m of debt.
- Operating profit covers interest at least five times over Operating income of −$19m against $28m of interest.
Moat
Weak moat
How hard Establishment Labs's competitive advantage looks for rivals to wear away, judged from 9 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 0 / 20
Cash operating profit has been a median -13.4% of total assets over 8 years.
- Pricing power 18 / 20
Gross margin has been a median 65.0%, moving by 4.3 percentage points (standard deviation) across 9 years.
- Durability 10 / 20
Operating margin has been a median -35.4%; its worst year was -43.2%.
- Cash conversion 0 / 20
Free cash flow was positive in 0 of 9 years, at a median -43.4% of revenue.
- Discipline 3 / 20
The diluted share count rose 26.3% over five years; stock-based pay has been a median 7.3% of revenue.
AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.
Compare with peers
- Cerus Corp statistics
- Lemaitre Vascular Inc statistics
- Orthopediatrics Corp statistics
- Axogen, Inc. statistics
- Si-bone, Inc. statistics
Head to head: CERS vs ESTAESTA vs LMATESTA vs KIDSESTA vs SIBN
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies